Trials / Completed
CompletedNCT01963598
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 253 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients with sarcopenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1033 (SAR391786) | |
| DRUG | placebo |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-01-01
- Completion
- 2015-02-01
- First posted
- 2013-10-16
- Last updated
- 2016-03-28
Locations
43 sites across 4 countries: United States, France, Netherlands, Spain
Source: ClinicalTrials.gov record NCT01963598. Inclusion in this directory is not an endorsement.